84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]梁博程,史曉林,許超,等.基于中藥系統(tǒng)藥理學(xué)方法研究六味地黃丸治療骨質(zhì)疏松癥的藥效成分、作用靶點(diǎn)及作用特點(diǎn)[J].中醫(yī)正骨,2019,31(04):1-7.
　LIANG Bocheng,SHI Xiaolin,XU Chao,et al.A study of pharmacodynamic components,action targets and characteristics of Liuwei Dihuang Wan(六味地黃丸)in treatment of osteoporosis using traditional chinese medicine systems pharmacology approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(04):1-7.
點(diǎn)擊復(fù)制

基于中藥系統(tǒng)藥理學(xué)方法研究六味地黃丸治療骨質(zhì)疏松癥的藥效成分、作用靶點(diǎn)及作用特點(diǎn)()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第31卷
期數(shù):
2019年04期
頁碼:
1-7
欄目:
基礎(chǔ)研究
出版日期:
2019-04-30

文章信息/Info

Title:
A study of pharmacodynamic components,action targets and characteristics of Liuwei Dihuang Wan(六味地黃丸)in treatment of osteoporosis using traditional chinese medicine systems pharmacology approach
作者:
梁博程; 史曉林; 許超; 吳連國; 何濱; 李琰華; 李敏
(浙江中醫(yī)藥大學(xué)附屬第二醫(yī)院,浙江 杭州 310005)
Author(s):
LIANG Bocheng; SHI Xiaolin; XU Chao; WU Lianguo; HE Bin; LI Yanhua; LI Min
The Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310005,Zhejiang,China
關(guān)鍵詞:
骨質(zhì)疏松;  六味地黃丸;  藥理作用;  基因本體論;  信號通路
Keywords:
osteoporosis;  Liuwei Dihuang Wan;  pharmacologic actions;  gene ontology;  signaling pathway
摘要:
目的:基于中藥系統(tǒng)藥理學(xué)方法探討六味地黃丸治療骨質(zhì)疏松癥(osteoporosis,OP)的藥效成分、作用靶點(diǎn)及作用特點(diǎn)。方法:在中藥綜合數(shù)據(jù)庫中檢索六味地黃丸中的已知化學(xué)成分,然后使用中醫(yī)藥分子機(jī)制生物信息學(xué)分析工具預(yù)測六味地黃丸已知化學(xué)成分的作用靶點(diǎn)。通過檢索DisGeNET數(shù)據(jù)庫和人工閱讀文獻(xiàn),查找OP相關(guān)靶基因和蛋白,通過與預(yù)測得到的作用靶點(diǎn)進(jìn)行交疊,篩選六味地黃丸治療OP的作用靶點(diǎn)。利用Cytoscape 3.7軟件自帶的BiNGO和ClueGO插件,分別對篩選出的靶點(diǎn)進(jìn)行基因注釋和信號通路富集分析。最后選取前期構(gòu)建的絕經(jīng)后OP疾病模型中的87個(gè)差異表達(dá)蛋白(基于血清蛋白質(zhì)組學(xué)篩選的絕經(jīng)后OP女性與絕經(jīng)后骨量正常女性的血清差異表達(dá)蛋白),與篩選出的六味地黃丸治療OP的作用靶點(diǎn)進(jìn)行交疊,篩選六味地黃丸治療OP的關(guān)鍵靶點(diǎn),通過分析原始數(shù)據(jù),確定相應(yīng)的中藥及其藥效成分。結(jié)果:通過檢索發(fā)現(xiàn)六味地黃丸化學(xué)成分130個(gè),其中熟地黃化學(xué)成分8個(gè)、山藥化學(xué)成分20個(gè)、山茱萸化學(xué)成分46個(gè)、澤瀉化學(xué)成分21個(gè)、牡丹皮化學(xué)成分18個(gè)、茯苓化學(xué)成分21個(gè); 茯苓與山茱萸、山茱萸與牡丹皮各含有1個(gè)相同化學(xué)成分,澤瀉與山茱萸含有2個(gè)相同化學(xué)成分。根據(jù)六味地黃丸化學(xué)成分共預(yù)測到1169個(gè)作用靶點(diǎn),其中君藥熟地黃作用靶點(diǎn)42個(gè),臣藥山茱萸和山藥作用靶點(diǎn)997個(gè),佐藥澤瀉、牡丹皮和茯苓作用靶點(diǎn)共622個(gè); 君藥與臣藥共有12個(gè)共同作用靶點(diǎn),君藥與佐藥有14個(gè)共同作用靶點(diǎn),臣藥與佐藥有472個(gè)共同作用靶點(diǎn),君藥、臣藥、佐藥共有6個(gè)共同作用靶點(diǎn)。經(jīng)檢索DisGeNET數(shù)據(jù)庫和人工閱讀文獻(xiàn),共檢索到OP相關(guān)靶點(diǎn)687個(gè),通過與預(yù)測到的六味地黃丸作用靶點(diǎn)交疊,共篩選出六味地黃丸治療OP的作用靶點(diǎn)142個(gè)。靶點(diǎn)基因注釋發(fā)現(xiàn),六味地黃丸治療OP的142個(gè)作用靶點(diǎn)主要參與了20種生物學(xué)過程,分布于8種細(xì)胞成分中,具有10種分子功能,其作用涉及骨重建、骨化、血管重塑、軟骨發(fā)育、肌肉發(fā)育、骨骼發(fā)育、維生素D代謝、維生素應(yīng)答、雌激素刺激應(yīng)答、破骨細(xì)胞分化、成骨細(xì)胞分化、骨礦化、Wnt信號通路和Samd信號通路等生物學(xué)行為的調(diào)控。信號通路富集分析發(fā)現(xiàn),119個(gè)信號通路被顯著富集,破骨細(xì)胞分化、NF-κB信號通路和卵巢類固醇生成等24個(gè)功能組被顯著富集,其中Wnt信號通路和與絕經(jīng)后OP密切相關(guān)的雌激素調(diào)控信號通路等在24個(gè)功能組中廣泛分布。通過將87個(gè)差異表達(dá)蛋白與篩選出的六味地黃丸治療OP的作用靶點(diǎn)交疊,篩選出血管緊張素原、載脂蛋白E、Dickkopf相關(guān)蛋白3、RAS相關(guān)蛋白7a和蛋白質(zhì)二硫鍵異構(gòu)酶共5個(gè)關(guān)鍵靶點(diǎn),對應(yīng)山茱萸、山藥、茯苓的6個(gè)藥效成分,包括馬兜鈴?fù)ⅵ?考繞咖烯、豆甾醇、尿囊素、鞘氨醇A及齒孔醇。結(jié)論:六味地黃丸治療OP的藥效成分包括山藥、山茱萸和茯苓所含化合物馬兜鈴?fù)ⅵ?考繞咖烯、豆甾醇、尿囊素、鞘氨醇A及齒孔醇,主要作用靶點(diǎn)包括血管緊張素原、載脂蛋白E、Dickkopf相關(guān)蛋白3、RAS相關(guān)蛋白7a和蛋白質(zhì)二硫鍵異構(gòu)酶。六味地黃丸治療OP具有多靶點(diǎn)、多系統(tǒng)協(xié)同作用的特點(diǎn)。
Abstract:
Objective:To explore the pharmacodynamic components,action targets and characteristics of Liuwei Dihuang Wan(六味地黃丸,LWDHW)in treatment of osteoporosis(OP)using traditional Chinese medicine(TCM)systems pharmacology approach.Methods:The known chemical components of LWDHW were searched out from traditional Chinese medicine integrative database(TCMID),and the action targets of known chemical components of LWDHW were predicted by using a bioinformatics analysis tool for molecular mechanism of raditional Chinese medicine(BATMAN-TCM).The OP-related target genes and proteins were searched out through retrieving DisGeNET database and reading the articles,and the action targets of LWDHW for treatment of OP were selected out through overlapping the OP-related target genes and proteins with the predicted action targets.Gene annotation and signal pathway enrichment analysis were performed on the selected targets respectively by using BiNGO and ClueGO plug-ins in Cytoscape 3.7 software.Eighty-seven proteins,which differentially expressed in serum of females with PMOP and postmenopausal females with normal bone mass,were selected out from the PMOP models to overlap with the selected action targets of LWDHW for treatment of OP,and the key targets of LWDHW for treatment of OP were selected out finally.The corresponding TCMs and their pharmacodynamic components were determined through analyzing the original data.Results:One hundred and thirty chemical components of LWDHW were found out through retrieving TCMID,including the chemical components of radix rehmanniae praeparata(8),rhizoma dioscoreae(20),fructus corni(46),rhizoma alismatis(21),cortex moutan radicis(18)and poria cocos(21).One identical chemical component was found in poria cocos and fructus corni and in fructus corni and cortex moutan radicis respectively,and two identical chemical components were found in rhizoma alismatis and fructus corni.One thousand one hundred and sixty-nine action targets were predicted according to the chemical components of LWDHW,including the action targets of radix rehmanniae praeparata(sovereign drug,42),fructus corni and rhizoma dioscoreae(minister drug,997)and rhizoma alismatis,cortex moutan radicis and poria cocos(assistant drug,622).The common action targets were found in sovereign drug and minister drug(12),sovereign drug and assistant drug(14),minister drug and assistant drug(472)and sovereign drug,minister drug and assistant drug(6).Six hundred and eighty-seven OP-related targets were searched out through retrieving DisGeNET database and reading the articles,and 142 action targets of LWDHW for treatment of OP were selected out by overlapping the OP-related targets with the predicted action targets of LWDHW.The results of gene annotation for the targets demonstrated that the 142 action targets of LWDHW for treatment of OP were mainly involved in 20 kinds of biological processes,distributed in 8 kinds of cell components and had 10 kinds of molecular functions,and played a role in the regulation of biological behaviors such as bone reconstruction,ossification,vascular remodeling,cartilage development,muscle development,bone development,vitamin D metabolism,response to vitamin,response to estrogen stimulation,osteoclast differentiation,osteoblast differentiation,bone mineralization,Wnt signaling pathway and Samd signaling pathway.The results of signal pathway enrichment analysis of the targets demonstrated that 119 signaling pathways were significantly enriched,and 24 functional groups including osteoclast differentiation,NF-κB signaling pathway and ovarian steroidogenesis were significantly enriched,and Wnt signaling pathway and PMOP-related estrogen regulation signaling pathway were widely distributed in the 24 functional groups.Five key targets,including angiotensinogen(AGT),apolipoprotein E(APOE),Dickkopf-related protein 3(DKK3),RAB7A and protein disulfide isomerase(PDI),were selected out through overlapping the 87 differentially expressed proteins with the selected action targets of LWDHW for treatment of OP,and they corresponded to the 6 pharmacodynamic components of fructus corni,rhizoma dioscoreae and poria cocos,including aristolone,alpha-corocalene,stigmasterol,allantoin,sphingosine A and eburicol.Conclusion:The pharmacodynamic components of LWDHW for treatment of OP include aristolone,alpha-corocalene,stigmasterol,allantoin,sphingosine A and eburicol,which are contained in rhizoma dioscoreae,fructus corni and poria cocos,and their main action targets include AGT,APOE,DKK3,RAB7A and PDI.LWDHW is characterized by synergistic effect of multiple targets and multiple systems in treatment of OP.

參考文獻(xiàn)/References:

[1] 《中國老年骨質(zhì)疏松癥診療指南》(2018)工作組,中國老年學(xué)和老年醫(yī)學(xué)學(xué)會(huì)骨質(zhì)疏松分會(huì).中國老年骨質(zhì)疏松癥診療指南(2018)[J].中國骨質(zhì)疏松雜志,2018,24(12):1541-1567. [2] 李繼鋼.骨質(zhì)疏松藥物治療研究進(jìn)展[J].中國處方藥,2018,16(4):17-18. [3] 中國老年學(xué)學(xué)會(huì)骨質(zhì)疏松委員會(huì)中醫(yī)藥與骨病學(xué)科組.中醫(yī)藥防治原發(fā)性骨質(zhì)疏松癥專家共識(2015)[J].中國骨質(zhì)疏松雜志,2015,21(9):1023-1028. [4] 魏戌,章軼立,謝雁鳴.原發(fā)性骨質(zhì)疏松癥中醫(yī)藥防治策略與研究方法[J].中國中醫(yī)藥信息雜志,2018,25(1):5-9. [5] 鄭春松,葉蕻芝,蔡亮亮,等.基于計(jì)算機(jī)模擬探討六味地黃丸治療骨關(guān)節(jié)炎的多成分-多靶點(diǎn)作用[J].中醫(yī)正骨,2013,25(1):11-13. [6] 王樂,徐無忌.六味地黃丸對兔椎間盤退變模型椎間盤組織中Ⅰ、Ⅱ型膠原表達(dá)的影響[J].中醫(yī)正骨,2016,28(8):1-7. [7] 賴艷妮,嚴(yán)一文,徐培平.基于系統(tǒng)藥理學(xué)探索莪術(shù)有效成分的藥理作用機(jī)制[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2017,23(14):177-182. [8] HUANG L,XIE D L,YU Y R,et al.TCMID 2.0:a comprehensive resource for TCM[J].Nucleic Acids Res,2018,46(D1):D1117-D1120. [9] LIU Z,GUO F,WANG Y,et al.BATMAN-TCM:a bioinformatics analysis Tool for molecular mechANism of traditional Chinese medicine[J].Sci Rep,2016,6:21146. [10] PIÑERO J,BRAVO À,QUERALT-ROSINACH N,et al.DisGeNET:a comprehensive platform integrating information on human disease-associated genes and variants[J].Nucleic Acids Res,2017,45(D1):D833-D839. [11] FRANZ M,LOPES CT,HUCK G,et al.Cytoscape.js:a graph theory library for visualisation and analysis[J].Bioinformatics,2016,32(2):309-311. [12] 史曉林,梁博程,姚建亮,等.基于TMT標(biāo)記聯(lián)合LC-ESI-MS/MS技術(shù)篩選絕經(jīng)后骨質(zhì)疏松癥的血清分子標(biāo)志物研究[J].中華骨科雜志,2015,35(10):1004-1010. [13] 謝麗華,陳娟,李生強(qiáng),等.六味地黃丸對絕經(jīng)后骨質(zhì)疏松癥腎陰虛證 JAK/STAT信號通路基因的影響[J].中國骨質(zhì)疏松雜志,2014,20(7):741-746. [14] 盧嚴(yán)方,林貫川,劉倩倩,等.六味地黃丸對絕經(jīng)期腎陰虛骨質(zhì)疏松癥的基因表達(dá)調(diào)控?cái)?shù)據(jù)分析[J].中國骨質(zhì)疏松雜志,2017,23(3):350-356. [15] 倪晨波.六味地黃丸對絕經(jīng)后骨質(zhì)疏松癥腎陰虛證相關(guān)基因CLCF1 mRNA表達(dá)的影響[D].福州:福建中醫(yī)藥大學(xué),2014. [16] 陳攀,徐志偉,敖海清.四逆散、六味地黃丸誘導(dǎo)神經(jīng)干細(xì)胞向神經(jīng)元分化及對Wnt1、Wnt3a、β-catenin mRNA表達(dá)的影響[J].時(shí)珍國醫(yī)國藥,2016,27(4):777-780. [17] 徐君翔,劉晨,張鵬,等.高血壓與中老年女性骨密度的關(guān)系[J].中國老年學(xué)雜志,2015,35(4):872-876. [18] 崔燎,陳槐卿.心血管藥物與骨質(zhì)疏松[J].中國骨質(zhì)疏松雜志,2004,10(4):141-148. [19] NOGUCHI T,EBINA K,HIRAO M,et al.Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos,NFATc1,and NF-κB pathway[J].Biochem Biophys Res Commun,2018,503(2):644-650. [20] 呂丹,陳煒,王書美,等.Dkk3系統(tǒng)性表達(dá)轉(zhuǎn)基因小鼠的建立[J].中國比較醫(yī)學(xué)雜志,2009,19(9):16-19. [21] BARDAI G,MOFFATT P,GLORIEUX F H,et al.DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta:diagnostic yield and mutation spectrum[J].Osteoporos Int,2016,27(12):3607-3613.

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(04):7.
[3]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(04):12.
[4]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[5]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):27.
[6]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(04):19.
[7]項(xiàng)旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(04):20.
[8]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時(shí)間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):5.
[9]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):21.
[10]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(04):16.
[11]姜朝陽,謝興文,徐世紅,等.六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥的研究進(jìn)展[J].中醫(yī)正骨,2020,32(04):38.
[12]匡浩銘,楊張琪,彭志飛,等.六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥療效和安全性的Meta分析[J].中醫(yī)正骨,2022,34(08):31.
　KUANG Haoming,YANG Zhangqi,PENG Zhifei,et al.Clinical efficacy and safety of Liuwei Dihuang Wan(六味地黃丸)for treatment of postmenopausal osteoporosis:a meta-analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(04):31.

備注/Memo

備注/Memo:
基金項(xiàng)目:國家自然科學(xué)基金項(xiàng)目(81803902) 通訊作者:李敏 E-mail:[email protected](收稿日期:2018-12-28 本文編輯:李曉樂)
更新日期/Last Update: 2019-10-08